|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome显示文摘Hepatitis B virus(HBV) continues to be a major cause of morbidity and mortality worldwide. It is estimated that about 350 million people throughout the world are chronically infected with HBV. Some of these people will develop hepatic cirrhosis with decompensation and/or hepatocellular carcinoma. For such patients, liver transplantation may be the only hope for cure or real improvement in quality and quantity of life. Formerly, due to rapidity of recurrence of HBV infection after liver transplantation, usually rapidly progressive, liver transplantation was considered to be contraindicated. This changed dramatically following the demonstration that hepatitis B immune globulin(HBIG), could prevent recurrent HBV infection. HBIG has been the standard of care for the past two decades or so. Recently, with the advent of highly active inhibitors of the ribose nucleic acid polymerase of HBV(entecavir, tenofovir), there has been growing evidence that HBIG needs to be given for shorter lengths of time; indeed, it may no longer be necessary at all. In this review, we describe genetic variants of HBV and past, present, and future prophylaxis of HBV infection during and after liver transplantation. We have reviewed the extant medical literature on the subject of infection with the HBV, placing particular emphasis upon the prevention and treatment of recurrent HBV during and after liver transplantation. For the review, we searched PubMed for all papers on the subject of 'hepatitis B virus AND liver transplantation'. We describe some of the more clinically relevant and important genetic variations in the HBV. We also describe current practices at our medical centers, provide a summary and analysis of comparative costs for alternative strategies for prevention of recurrent HBV, and pose important still unanswered questions that are in need of answers during the next decade or two. We conclude that it is now rational and cost-effective to decrease and, perhaps, cease altogether, the routine use of HBIG during and following liver transplantation for HBV infection. Here we propose an individualized prophylaxis regimen, based on an integrated approach and risk-assessment. | Tahereh Ghaziani Hossein Sendi Saeid Shahraz Philippe Zamor Herbert L Bonkovsky | 2014 | World Journal of Gastroenterology2014，20，39： | 7 |
| 2 | Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV显示文摘AIM: To determine the effect of Legalon-SIL (LS) on hepatitis C virus (HCV) core and NS5A expression and on heme oxygenase-1 (HMOX-1) and its transcriptional regulators in human hepatoma cells expressing full length HCV genotype 1b. METHODS: CON1 cells were treated with 50 μmol/L or 200 μmol/L LS. Cells were harvested after 2, 6 and 24 h. HCV RNA and protein levels were determined by quantitative real-time polymerase chain reaction and Western blotting, respectively. RESULTS: HCV RNA (core and NS5A regions) wasdecreased after 6 h with LS 200 μmol/L (P < 0.05). Both 50 and 200 μmol/L LS decreased HCV RNA levels [core region (by 55% and 88%, respectively) and NS5A region (by 62% and 87%, respectively) after 24 h compared with vehicle (dimethyl sulphoxide) control (P < 0.01). Similarly HCV core and NS5A protein were decreased (by 85%, P < 0.01 and by 65%, P < 0.05, respectively) by LS 200 μmol/L. Bach1 and HMOX-1 RNA were also downregulated by LS treatment (P < 0.01), while Nrf2 protein was increased (P < 0.05).CONCLUSION: Our results demonstrate that treatment with LS downregulates HCV core and NS5A expression in CON1 cells which express full length HCV genotype 1b, and suggests that LS may prove to be a valuable alternative or adjunctive therapy for the treatment of HCV infection. | Marjan Mehrab-Mohseni Hossein Sendi Nury Steuerwald Sriparna Ghosh Laura W Schrum Herbert L Bonkovsky | 2011 | World Journal of Gastroenterology2011，17，13： | 3 |
| 3 | Hepatitis C , porphyria cutanea tarda and liver iron: an update显示文摘 | F. Ryan Caballes Hossein Sendi Herbert L. Bonkovsky | 2012 | Liver Int2012，，6： | 1 |
| 4 | Hepatitis C , porphyria cutanea tarda and liver iron: an update显示文摘 | F. Ryan Caballes Hossein Sendi Herbert L. Bonkovsky | 2012 | Liver Int2012，，6： | 1 |
| 5 | CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA显示文摘 | Hossein Sendi Marjan Mehrab-Mohseni Saeid Shahraz Helene Norder Seyed-Moayed Alavian Babak Noorinayer Mohammad R. Zali Paul Pumpens Herbert L. Bonkovsky Lars O. Magnius | 2009 | Journal of Clinical Virology2009，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员